Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conference

Rhea-AI Summary

Ultragenyx Pharmaceutical (NASDAQ: RARE) will have CEO Emil D. Kakkis present at the Goldman Sachs 42nd Annual Healthcare Conference on June 10, 2021, at 3:00 PM ET. The presentation will be available via a live and archived webcast on the company’s website, accessible for 90 days following the event.

Ultragenyx is focused on developing therapies for serious rare genetic diseases and has a diverse portfolio aimed at addressing high unmet medical needs.

News Market Reaction – RARE

-2.31%

-2.31% Session move

In the trading session that priced this news, RARE declined 2.31%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NOVATO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Goldman Sachs 42^nd Annual Healthcare Conference on Thursday, June 10, 2021 at 3:00 PM ET.

The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing to patients novel therapies for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Joshua Higa
415-475-6370

FAQ

When will Ultragenyx present at the Goldman Sachs Healthcare Conference?

Ultragenyx will present on June 10, 2021, at 3:00 PM ET.

How can I access the Ultragenyx presentation at the conference?

The live and archived webcast can be accessed on Ultragenyx's website.

What is the focus of Ultragenyx Pharmaceutical?

Ultragenyx focuses on developing therapies for serious rare and ultra-rare genetic diseases.

What is the ticker symbol for Ultragenyx Pharmaceutical?

The ticker symbol for Ultragenyx is RARE.

How long will the Ultragenyx presentation be available for replay?

The presentation will be available for replay for 90 days after the event.